Daily Respiratory Research Analysis
Analyzed 155 papers and selected 3 impactful papers.
Summary
Three impactful studies advance respiratory medicine across risk stratification and mechanisms. A prospective multicenter study derived and externally validated the RED score to predict time to next procedure after aspiration in malignant pleural effusion. Another multicenter cohort demonstrated that the Prognostic Nutritional Index improves 30-day mortality prediction and refines ESC risk stratification in acute pulmonary embolism, while a systematic review showed adults hospitalized with RSV face substantial cardiac event risks, exceeding influenza for heart failure.
Research Themes
- Risk stratification in acute pulmonary embolism using nutritional-inflammation biomarkers
- Procedure timing prediction in malignant pleural effusion
- Cardiac complications following respiratory viral infection (RSV)
Selected Articles
1. Time to next procedure in patients with malignant pleural effusion undergoing aspiration: derivation and initial validation of the RED score.
In a 10-center prospective cohort (n=241), the RED score—combining baseline respiratory rate, ultrasound effusion depth, and dyspnea VAS—predicted time to next pleural intervention after aspiration for malignant pleural effusion. Discrimination was moderate (AUC 0.73–0.75) and externally validated in two cohorts.
Impact: Provides a simple, ultrasound-enabled tool to schedule follow-up and select definitive interventions (e.g., IPC or pleurodesis) by anticipating reaccumulation timing.
Clinical Implications: Use RED score at aspiration to triage patients likely to reaccumulate rapidly toward earlier definitive management and prioritize closer review; may reduce repeat unscheduled procedures and improve resource allocation.
Key Findings
- Derivation cohort (n=180): respiratory rate, ultrasound effusion depth, and dyspnea VAS independently predicted time to next procedure.
- Model discrimination AUCs were 0.73 and 0.75; initial external validation in two cohorts (n=31 and n=57) showed reasonable performance.
- Three-month follow-up demonstrated practical applicability for planning repeat drainage vs definitive pleural strategies.
Methodological Strengths
- Prospective, multicenter design with prespecified candidate predictors
- External validation in two independent cohorts
Limitations
- Modest sample sizes in validation cohorts may limit precision
- Short (3-month) follow-up and potential variability in ultrasound measurements across centers
Future Directions: Prospective impact analyses to test clinical workflow integration (e.g., decision support), calibration in diverse settings, and comparison against biomarker-augmented models.
INTRODUCTION: In patients with malignant pleural effusions (MPE), pleural fluid reaccumulates at variable rates following therapeutic aspiration. The aim of this study was to identify variables which predict time to next procedure and use them to develop a predictive score. METHODS: This prospective observational cohort study in 10 British hospitals recruited patients with known or suspected malignant effusions undergoing therapeutic aspiration. Follow-up lasted 3 months and assessed time to next clinically indicated pleural procedure. Regression analysis was performed to identify independent variables predicting time to next procedure, and a score derived. Initial validation was done in two external cohorts. MEASUREMENTS AND MAIN RESULTS: 241 patients were recruited. Within the derivation cohort (n=180), baseline respiratory rate (R), pleural effusion depth on ultrasound (E) and dyspnoea measured using a visual analogue scale (D) (combined to form the RED score) were independent predictors of time to next procedure. Predictive models provided areas under the receiver operator curve of 0.73 and 0.75. Initial validity testing in two cohorts (n=31, n=57) demonstrated reasonable predictive value. CONCLUSIONS: In patients with MPE, baseline respiratory rate, pleural effusion depth on ultrasound and dyspnoea predict time to next procedure. TRIAL REGISTRATION NUMBER: ISRCTN16567838.
2. The prognostic nutritional index improves risk stratification for acute pulmonary embolism.
Across derivation (n=1,163) and two validation cohorts, higher PNI independently predicted lower 30-day and in-hospital mortality in acute pulmonary embolism. Adding PNI improved ESC risk model performance and identified a PNI ≤42.5 cutoff that further stratified intermediate-risk patients with markedly different 30-day mortality.
Impact: Introduces a simple, routinely available biomarker to refine guideline-based risk models and target monitoring or escalated therapy within the large intermediate-risk population.
Clinical Implications: Incorporate PNI into APE assessment to identify intermediate-risk patients at higher short-term mortality who may benefit from closer monitoring, early echocardiography, or consideration of escalated anticoagulation/thrombolysis according to bleeding risk.
Key Findings
- Higher PNI independently associated with lower 30-day and in-hospital mortality after multivariable adjustment.
- Adding PNI improved ESC model discrimination for 30-day mortality.
- PNI ≤42.5 effectively identified higher-risk subgroups within ESC intermediate-low and intermediate-high categories (4.7x and 6x higher 30-day mortality).
Methodological Strengths
- Derivation plus internal and external validation cohorts
- Incremental value demonstrated over an established guideline model
Limitations
- Observational design susceptible to residual confounding (e.g., inflammation and malnutrition)
- Generalizability of the cutoff (PNI ≤42.5) requires broader external validation
Future Directions: Prospective implementation studies to evaluate clinical decision impact and outcomes; assess synergy with imaging (RV dysfunction) and biomarkers (troponin/BNP); explore dynamic PNI changes.
Risk stratification guides management in acute pulmonary embolism (APE), yet current models have limitations. We investigated the Prognostic Nutritional Index (PNI) as a potential biomarker to refine risk assessment. Analyzing 1,163 discovery, 208 internal-validation, and 212 external-validation APE patients, we found that a higher PNI was independently associated with lower 30-day and in-hospital mortality after multivariable adjustment. Incorporating PNI into the European Society of Cardiology (ESC) risk model improved its predictive performance for 30-day mortality. Crucially, a PNI ≤42.5 effectively stratified intermediate-risk patients, identifying subgroups with 4.7- and 6-fold higher 30-day mortality in the intermediate-low- and intermediate-high-risk categories, respectively. These findings position PNI as a simple, valuable tool for enhancing precision in APE risk stratification.
3. The risk of cardiac disease events after respiratory syncytial virus disease: a systematic literature review and meta-analysis.
Across 28 studies, hospitalized adults with RSV had high cardiac event rates: any cardiac event 19.2%, heart failure 15.7%, and ACS 5.4%. Compared with influenza, RSV conferred higher risk of heart failure (RR 1.3), underscoring clinically relevant cardiac surveillance needs following RSV.
Impact: Quantifies absolute and relative cardiac risks after RSV disease, informing inpatient monitoring, biomarker testing, and discharge planning, particularly in older adults and those with comorbidities.
Clinical Implications: Consider routine cardiac risk assessment (e.g., troponin/BNP, ECG, echocardiography when indicated) in hospitalized adults with RSV, with targeted monitoring for heart failure; prioritize vaccination and prevention strategies in high-risk populations.
Key Findings
- Pooled cardiac event rates in hospitalized RSV: any cardiac event 19.2%, heart failure 15.7%, ACS 5.4%.
- RSV associated with higher risk of heart failure versus influenza (RR 1.3; 95% CI 1.1–1.6).
- Cardiac event-related mortality ranged 1.1–9.8%, indicating clinically meaningful outcomes beyond respiratory morbidity.
Methodological Strengths
- Systematic search with quality assessment and random-effects meta-analysis
- Comparative synthesis versus influenza provides clinical context
Limitations
- Heterogeneity across observational studies and outcome definitions
- Potential confounding from comorbidity burden and surveillance biases
Future Directions: Time-to-event analyses defining peak risk windows post-RSV, prospective cohorts with standardized cardiac assessments, and evaluation of preventive strategies in high-risk groups.
BACKGROUND: Respiratory syncytial virus (RSV) infection has been associated with an increased risk of cardiac events. This systematic review aims to synthesise the evidence on the absolute and relative risks of cardiac events in adults with RSV disease. METHODS: We searched Embase, PubMed and grey literature sources for studies published between 1 January 2000 and 6 March 2024, reporting on cardiac events in adults with RSV disease. Study quality was assessed using a validated checklist. Absolute and relative risks of cardiac events following RSV disease were summarised and pooled estimates using random effects meta-analysis were calculated. RESULTS: Of 3887 publications, 28 met the inclusion criteria. Among hospitalised patients with RSV disease (25 studies), the pooled estimates showed that 19.2% (95% CI 15.1-24.2) experienced any cardiac event (including specific and unspecific events and combinations of cardiac events), 15.7% (95% CI 14.8-16.5%) heart failure (HF) and 5.4% (95% CI 3.1-9.5%) acute coronary syndrome (ACS). Cardiac event-related mortality ranged from 1.1 to 9.8%. Compared to influenza patients, those with RSV disease had a risk ratio of 1.2 (95% CI 1.1-1.4) for any cardiac event, 1.3 (95% CI 1.1-1.6) for HF and 1.2 (95% CI 0.9-1.5) for ACS. CONCLUSION: RSV disease poses significant risks beyond respiratory illness, including cardiac events, among older adult patients. RSV was associated with a higher risk of HF compared to influenza. Further research is needed to more precisely define the risk period of cardiac events following RSV disease.